We are excited to announce that we have finalized an agreement with Anda, a wholly owned subsidiary of Teva Pharmaceuticals, to dispense an unbranded Selarsdi product, ustekinumab-aekn, as of July 2025. This will deliver upfront, real-time savings for our partners and patients compared to brand Stelara. To learn more about our biosimilar-first strategy, read today’s press release. https://lnkd.in/gU662KuB
